Literature DB >> 30363359

Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating Scale.

Muhittin C Akbostanci1,2, Ece Bayram2, Volkan Yilmaz1, Sefer Rzayev1, Serhat Özkan3, Ayse Bora Tokcaer4, Esen Saka5, Fatma N Durmaz Celik3, Banu Özen Barut6, Zeynep Tüfekcioglu7, Ahmet Acarer8, Hatice Balaban9, Sevda Erer10, Okan Dogu11, Seda Kibaroglu12, Nursel Aydin1, Hasmet Hanagasi7, Bülent Elibol5, Murat Emre7, Glenn T Stebbins13, Christopher G Goetz13.   

Abstract

BACKGROUND: Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Unified Dyskinesia Rating Scale (UDysRS) were developed as standard tools to rate Parkinson's disease (PD) and drug-induced dyskinesias of PD. As these scales have become widely used, there is a need for translation to non-English languages. Here we present the standardization for the Turkish translations.
METHODS: The scales were translated into Turkish and then back-translated to English. These back-translations were reviewed by the MDS team. After cognitive pretesting, movement disorder specialists from nine centers tested 352 patients for MDS-UPDRS, and 250 patients for UDysRS. Confirmatory factor analyses (CFAs) were used to determine if the factor structures for the reference standards could be confirmed in the Turkish data. The comparative fit indexes (CFIs) for the scales were required to be 0.90 or higher. Exploratory factor analyses (EFAs) were conducted to explore the underlying factor structure without the constraint of a pre-specified factor structure.
RESULTS: For both scales, the CFIs were 0.94 or greater as compared to the reference standard factor structures. The factor structures were consistent with that of reference standards, although there were some differences in some areas as compared to the EFA of the reference standard dataset. This may be due to the inclusion of patients with different stages of PD and different cultural properties of raters and patients.
CONCLUSIONS: These results demonstrate that the Turkish translations of MDS-UPDRS and UDysRS have adequate clinimetric properties. They are established as the official translations and can be reliably used in Turkish speaking populations.

Entities:  

Keywords:  Dyskinesia; Parkinson's disease; rating scale

Year:  2017        PMID: 30363359      PMCID: PMC6174365          DOI: 10.1002/mdc3.12556

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  8 in total

1.  Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease.

Authors:  David A Gallagher; Christopher G Goetz; Glenn Stebbins; Andrew J Lees; Anette Schrag
Journal:  Mov Disord       Date:  2011-09-13       Impact factor: 10.338

2.  IPMDS-Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS-UPDRS and UDysRS.

Authors:  Christopher G Goetz; Glenn T Stebbins; Lu Wang; Nancy R LaPelle; Sheng Luo; Barbara C Tilley
Journal:  Mov Disord Clin Pract       Date:  2014-05-14

3.  Independent Spanish Validation of the Unified Dyskinesia Rating Scale.

Authors:  Esther Cubo; Christopher G Goetz; Glenn T Stebbins; Nancy R LaPelle; Barbara C Tilley; Lu Wang; Sheng Luo
Journal:  Mov Disord Clin Pract       Date:  2014-08-05

4.  Official Japanese Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale: validation against the original English version.

Authors:  Kenichi Kashihara; Tomoyoshi Kondo; Yoshikuni Mizuno; Seiji Kikuchi; Sadako Kuno; Kazuko Hasegawa; Nobutaka Hattori; Hideki Mochizuki; Hideo Mori; Miho Murata; Masahiro Nomoto; Ryosuke Takahashi; Atsushi Takeda; Yoshio Tsuboi; Yoshikazu Ugawa; Mitsutoshi Yamanmoto; Fusako Yokochi; Fumihito Yoshii; Glenn T Stebbins; Barbara C Tilley; Sheng Luo; Lu Wang; Nancy R LaPelle; Christopher G Goetz
Journal:  Mov Disord Clin Pract       Date:  2014-09-01

Review 5.  The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations.

Authors: 
Journal:  Mov Disord       Date:  2003-07       Impact factor: 10.338

6.  Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Authors:  Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz
Journal:  J Neurol       Date:  2012-08-05       Impact factor: 4.849

7.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

Authors:  Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2008-11-15       Impact factor: 10.338

8.  The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.

Authors:  Christopher G Goetz; John G Nutt; Glenn T Stebbins
Journal:  Mov Disord       Date:  2008-12-15       Impact factor: 10.338

  8 in total
  2 in total

1.  Clinical evaluation and resting state fMRI analysis of virtual reality based training in Parkinson's disease through a randomized controlled trial.

Authors:  Farzin Hajebrahimi; Halil Aziz Velioglu; Zubeyir Bayraktaroglu; Nesrin Helvaci Yilmaz; Lutfu Hanoglu
Journal:  Sci Rep       Date:  2022-05-16       Impact factor: 4.996

2.  Effects of LSVT-BIG via telerehabilitation on non-motor and motor symptoms and quality of life in Parkinson's disease.

Authors:  Yasemin Ekmekyapar Fırat; Türkan Turgay; Selver Seval Soğan; Pınar Günel Karadeniz
Journal:  Acta Neurol Belg       Date:  2022-09-29       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.